Home
Valuation

Work Area: Valuation

<em>Storage Wars:</em> the price of overlooking hidden intangible assets

Storage Wars: the price of overlooking hidden intangible assets

Companies are failing to conduct proper due diligence assessments that consider intangible assets, which is proving detrimental to their organisation’s true value.

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

Latest content

Why IP valuation in Asia has yet to take off

Although various government-led programmes have emerged over the years to encourage activity in the field, writes Joyce Ng, professionals reveal that a lack of transaction data and an absence of corporate buy-in is preventing it from going mainstream

22 June 2022

GSK’s $3.3 billion buyout shows vaccine IP boom goes beyond mRNA

Affinivax acquisition based on platform tech licensed from Boston Children’s Hospital

06 June 2022

New 4G/5G landscape shows which SEP owners have strongest global coverage

Tech+IP Capital report proposes new methodology for looking at patent portfolio geography, finding Qualcomm’s 4G holdings have unmatched reach

02 June 2022

Report questions high published royalty rates for voice codec SEPs

Analysis from Stout suggests rates sought by certain Enhanced Voice Services (EVS) patent owners are out of line with the overall 3G/4G/5G FRAND landscape

18 May 2022

Stealthy biotech buys up patent portfolios in string of recent deals

Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months

04 May 2022

Dealing with 5G disappointment

The latest wireless standard hasn’t yet found its ‘killer app’ for consumers, and it’s affecting licensing negotiations

23 April 2022

The advantages of using hedonic regression to measure the value of standardised technologies

Hedonic regression is a dependable and impartial way to estimate the value of a standardised technology. Further, it can be applied to a range of products, especially those with multiple features.

13 April 2022

CRISPR FTO complexities not going anywhere in wake of Broad Institute victory, says IP chief on the CVC side

Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech

04 April 2022

Five key takeaways from IPBC Europe

Returning from two action-packed days in London, IAM Deputy Editor Adam Houldsworth reflects on the surprising state of corporate UPC strategies, the rise of AI, FRAND fireworks and more

02 April 2022

Ocean Tomo acquired by global consulting firm J.S. Held

Two years after private equity buyout, the pioneering IP advisory firm led by Jim Malackowski changes hands again

30 March 2022

Unlock unlimited access to all IAM content